Survey: Pharma Drives Innovation in Digital Health but Doesn’t Always Stick the Landing
A recent survey of 450 healthcare executives found that 92% agreed that pharma-sponsored digital health solutions can add value to [...]
UCB’s Psoriasis Drug’s FDA Application on Pause Due to Facility Inspection Issues
The US Food and Drug Administration (FDA) has temporarily halted the approval process for UCB’s psoriasis drug bimekizumab on concerns [...]
Moderna’s Ousted CFO may Lose $700,000 Severance
Days after the end of Jorge Gomez’s one-day stint as CFO of Moderna, the company has announced that Gomez has [...]
Positive Results Announced for Bristol Meyer Squibb’s Plaque Psoriasis Trial
Bristol Meyer Squib (BMS) has released promising two-year results for deucravacitinib, its psoriasis therapeutic. The results show the drug was [...]
Roche Takes Second Hit this Week with Launch of $0 Copay Esbriet Copycat
Just days after the failure of Roche’s massive TIGIT Phase III trial, Sandoz has released the first generic of Esbriet, [...]
RWJ Foundation Study Reveals Unhealthiest County US State
Health disparities in the US exist on the state and county level, with several rural areas experiencing significantly higher levels [...]
CSL’s Acquisition of Vifor Pharma Hits Antitrust Snags
The multinational biotech CSL’s planned purchase of Vifor Pharma has been put on pause due to antitrust concerns. The $11.7 [...]
Takeda Focuses on Reducing Debt as Vyvanse Patent Loss Looms
The drugmaker Takeda has ramped up its efforts in reducing its debt burder, with plans to pay off another 500 [...]
FDA Roundup – Week of May 10th
In the latest weekly FDA roundup, the agency has approved the immunomodulatory COVID-19 drug for use in hospitalized adult patients [...]
AbbVie and Teva Seek $5 Billion Opioid Litigation Settlements
Abbvie and Teva are looking towards an exit from their opioid litigation woes that could cost the two upwards of [...]
Abortion Draft Opinion Reignites Push for Over-the-counter Birth Control
The leaked US Supreme Court draft opinion on abortion rights has spurred additional urgency in efforts to gain FDA approval [...]
Pfizer Purchases Biohaven; Gains Rights to Leading Migraine Drug
Pfizer has announced an $11.6 billion deal to acquire the biotech Biohaven. This deal gives Pfizer rights to Nurtec, a [...]
Johnson & Johnson Backs Out of Bavarian Nordic HPV and HBV Vaccine Collaborations
J&J has announced that it is pulling out of hepatitis B virus (HBV) and human papillomavirus (HPV) vaccine development partnerships [...]
Intra-Cellular Launches New Bipolar Ad Campaign for Calypta
Intra-Cellular’s schizophrenia drug Calypta has recently gained FDA approval for bipolar depression. In response, the company has launched a aggressive [...]
Nonprofit Promises $1 a Day Insulin
Many Americans living with diabetes are forced to ration the insulin they need, potentially worsening their condition. Efforts to tackle [...]
Endpoints Peer Review: Biogen Searches for a CEO, Roivant Selects Srini Ramanathan as CDO
In the latest Endpoints Peer Review, Biogen looks for a new head to replace its CEO, Michel Vounatsos. The company [...]
Big Pharma Could Nearly Purchase Entire Small-Mid Cap Biotech Sector
A recent analysis shows that that the top 20 pharma companies combined could purchase over 600 biotechs, nearly every biotech [...]
Avoiding CAPA Overload During Regulatory Compliance Efforts
The path to regulatory compliance is beset with obstacles that can grind down market efforts to a halt. One major [...]
AstraZeneca Plans to Construct New R&D Center in the US
AstraZeneca has announced its plans to construct a new research and development site in Cambridge, Massachusetts. The new facility will [...]
Abbvie Scraps Cystic Fibrosis Triplet Therapy
Abbvie announced that it is dropping its triplet therapy for cystic fibrosis (CF) after a disappointing interim analysis in a [...]
Roche’s Oral Breast Cancer Drug Disappoints in Phase II Study
The pharma manufacturer Roche has announced discouraging results for its oral breast cancer drug giredestrant. Results show that the drug [...]
Realizing the “Grand Bargain” of Fair Drug Access and Pricing
Balancing the needs and means of patients with the interests of providers, payers, and drugmakers through fair drug prices is [...]
US Federal Judge Rules Bankruptcy Won’t Get Johnson & Johnson Off the Hook with New Talc Lawsuits
Although Johnson & Johnson’s (J&J) recent bankruptcy filing was a success, worries aren’t over for the company as they prepare [...]
Webinar: Trust: – the Missing Link Impacting Pharma’s Patient Services
Patients have become increasingly interested in support services in recent years, in no small part due to the COVID-19 pandemic. [...]
Language in FDA Decisions Could Signal Increased Scrutiny in Approval Decision-making
The wording in the US Food and Drug Administration’s (FDA) recent decision not to approve Pfizer and Myovant’s endometriosis application [...]